A Porphyrinic Covalent Organic Polymer Nanoplatform for Carborane Delivery and Multifunctional Imaging-Guided Boron Neutron Capture Therapy of Breast Cancer Authors: Jing Ren, Tingran Wang, Changmin Zuo, Ruiping Zhang, Liping Li Published: 2026 ABSTRACT IntroductionThe advancement of boron neutron capture therapy (BNCT) is critically dependent on the development of efficient and traceable boron delivery agents.MethodsWe designed and synthesized a porphyrin-based covalent organic polymer (T-COP) loaded with ortho-carborane (o-CB) and surface-functionalized with DSPE-PEG2000, successfully constructing a novel nanoplatform (T-COP@o-CB NPs). This platform enables real-time imaging-guided boron neutron capture therapy (BNCT), providing a new strategy for the treatment of breast cancer.ResultsThe resulting nanocomposite exhibits a high boron content (28.82 wt%), excellent colloidal stability, and pronounced fluorescence derived from the porphyrin building blocks, thereby enabling real-time tracking. In vitro, T-COP@o-CB NPs have outstanding biocompatibility, efficient cellular uptake, and prolonged intracellular retention in 4T1 breast cancer cells. In vivo fluorescence imaging confirms effective tumor localization and retention following intratumoral injection. Most notably, in a subcutaneous breast cancer mouse model, the T-COP@o-CB NPs with thermal neutron irradiation achieve 73.04% tumor inhibition compared to all control groups, while exhibiting no significant systemic toxicity as validated by body weight monitoring and histopathological analysis.ConclusionThis work presents a promising theranostic platform that combines high boron loading, inherent self-imaging capability, and effective tumor inhibition, offering a new strategy for precise and enhanced BNCT. Introduction Radiotherapy remains a cornerstone of clinical treatment for over 70% of cancer patients, primarily employing low linear energy transfer (LET) radiation to eliminate tumor tissue. However, conventional radiotherapy often inflicts damage on surrounding healthy tissues, leading to various adverse effects.1 Consequently, there is an urgent need to develop innovative and practical cancer treatment modalities. Boron neutron capture therapy (BNCT), a recently approved frontier radiotherapy, represents an emerging binary therapeutic approach. In BNCT, boron-containing tumor-targeting drugs, upon reaction with thermal neutrons, can generate localized radiation to selectively eradicate tumor cells.2 The technique relies on selectively loading tumor cells with 10B-enriched pharmaceuticals, followed by irradiation with epithermal neutron beams, typically produced by accelerators. The ensuing neutron capture reaction yields high-LET α particles and 7Li particles. With a travel distance of approximately 5–9 μm—comparable to the diameter of a single cell—these particles enable precise tumor cell destruction while largely sparing adjacent healthy tissue.3 Although BNCT offers superior accuracy and safety compared to traditional radiotherapy, its efficacy hinges on the efficient delivery of boron agents. Currently, only two small-molecule boron delivery agents—4-borono-L-phenylalanine (BPA) and sodium borocaptate (BSH)—are approved by the US Food and Drug Administration for clinical use in BNCT.4 Despite having over 60 years of clinical trial experience with BNCT agents, the total number of treated cases worldwide remains limited to only a few thousand, reflecting slow overall progress in this field. This situation is primarily due to the limitations of current boron agents, which are mainly small-molecule compounds. Challenges arise in achieving sufficient boron concentration within deep-seated tumor lesions due to the rapid metabolism of drugs, biological barriers, restricted blood supply caused by uneven distribution of blood vessels, rapidly proliferating tumors, and high interstitial pressure.5 Therefore, the development of novel boron agents with high tumor-targeting capability and effective intra-tumoral retention is crucial for enhancing the precision of BNCT and facilitating its clinical translation. To overcome the limitations of clinically approved boron agents, boron-enriched nanodrugs have been investigated, demonstrating longer cellular retention times compared to small-molecule boron agents.6 Among them, organic boron-containing nanoparticles (NPs) are considered highly efficient delivery vehicles, such as boron-containing liposomes,7 boron-loaded polymer nanoparticles,8 boron-containing dendritic molecules,9 boron-containing micelles,10 and so on. Covalent organic polymers (COPs) constitute an emerging class of amorphous or semi-crystalline porous materials constructed via strong covalent bonds between organic building blocks.11–13 Their periodic structures, pre-designable skeletons, large surface areas, and inherent biocompatibility endow COPs with excellent chemical and thermal stability, positioning them as promising platforms for anticancer drug delivery.14–17 Liu et al developed and assessed DSPE-PEG2000-functionalized, carborane-based covalent organic polymer nanoparticles (DSPE-BCOP-5T) for biocompatibility and PET/CT-guided BNCT capability.18 Subsequently, they proposed a micrometer-scale B-COF as a boron capsule loaded with imiquimod for combined BNCT-immunotherapy.19 Despite these promising demonstrations, the application of COPs (particularly boronate ester-linked COPs loaded with carborane) for BNCT visualization of drug delivery remains insufficiently explored. Herein, we designed a facile synthesis of a real-time imaging-capable boron nanocomposite based on a boronate ester-linked COP (T-COP@o-CB NPs). The nanocomposite exhibits high boron content, excellent biocompatibility, and prolonged tumor retention, enabling precise boron delivery and treatment monitoring (Figure 1). Specifically, we note that BPA and BSH suffer from low boron loading (typically <10 wt%), poor tumor selectivity, and rapid clearance, while existing COP-based BNCT systems either lack imaging capability or have limited boron payload. Our system surpasses these with a boron content of 28.82 wt%, built-in fluorescence tracking, and PEG-mediated steric stabilization. Collectively, this approach is anticipated to alleviate the suffering associated with radiotherapy, provide a new option for breast cancer patients seeking breast conservation, and significantly improve treatment outcomes and quality of life. While intratumoral injection used in this proof of concept study ensures high local boron concentration, systemic administration (eg, intravenous) would be required for clinical translation of metastatic cancers. Challenges such as rapid clearance, nonspecific distribution, and potential toxicity must be addressed. Future work will focus on surface engineering to enhance tumor targeting ability and long circulating properties. Figure 1Schematic illustration of T-COP@O-CB NPs application for boron neutron capture therapy in breast cancer.20The illustration depicts the application of T-COP@O-CB NPs for boron neutron capture therapy in breast cancer. The top section shows the synthesis process, starting with T-COP, which is combined with O-CB to form T-COP@O-CB. This is further modified with DSPE-PEG subscript 2000 to create T-COP@O-CB NPs. The bottom section illustrates the application, beginning with the injection of the nanocomposite into a tumor in a mouse. The process includes real-time monitoring and enhanced tumor retention and deep penetration. A thermal neutron interacts with boron subscript 10, leading to high therapeutic efficacy. The illustration highlights four key points: new boron-rich covalent organic polymer, real-time monitoring, enhanced tumor retention and deep penetration and high therapeutic efficacy.Illustrated workflow showing nanoparticle preparation, tumor targeting, imaging, and therapeutic delivery processes. Schematic illustration of T-COP@O-CB NPs application for boron neutron capture therapy in breast cancer.20 Materials and Methods Materials All reagents were used as received without further purification. 4-(1,3,2-dioxaborinan-2-yl)benzaldehyde was purchased from Anhui Zesheng Technology Co., Ltd. 1,4-phenylenediboronic acid was obtained from Shanghai Haohong Biomedical Technology Co., Ltd. Pyrrole, 1,4-dioxane, and mesitylene were sourced from Shanghai Aladdin Biochemical Technology Co., Ltd. Ortho-carborane was purchased from Shanghai Haohong Biomedical Technology Co., Ltd. The Cell Counting Kit-8 (CCK-8) was obtained from Sevenbio (Beijing, China). The Calcein-AM/PI double staining kit was purchased from Beijing, China. DMEM medium, fetal bovine serum (FBS), trypsin, penicillin, and streptomycin were obtained from Sangon Biotech (Shanghai) Co., Ltd. Female Balb/c mice (6–8 weeks old, 18–20 g) were obtained from Beijing Charles River Laboratory Animal Technology Co., Ltd. (China). Deionized (DI) water was used throughout all experiments. Synthesis of T-COP 1,4-Benzenediboronic acid (BDBA) (150 mg, 0.9 mmol), porphyrin-5,10,15,20-tetrayltetrakis(benzene-4,1-diyl)tetraboronic acid (ATPP) (29.63 mg, 0.0375 mmol), 1,3,5-trimethylbenzene (1.9 mL), and 1,4-dioxane (0.1 mL) were mixed in a heat-resistant glass tube. The tube was then subjected to three freeze-pump-thaw cycles: it was immersed in liquid nitrogen for 3–5 min until complete solidification, evacuated under high vacuum (< 10−3 mbar) for 5–7 min while maintaining the frozen state, then sealed and warmed to room temperature for 10 min until completely thawed. After the final cycle, the tube was sealed under vacuum and heated at 120 °C for 72 h. The resulting green product was collected by filtration under reduced pressure using a circulating water vacuum pump, washed three times with anhydrous acetone on the filter, and then dried under vacuum for 24 h. The isolated yield of T-COP was 30.51%. Preparation of the T-COP@o-CB NPs T-COP (30 mg) and o-CB (60 mg) were mixed in 2 mL of 1,4-dioxane in a round-bottom flask and sonicated using a probe ultrasonicator at 200 W, 40 kHz, with the water bath maintained at 25 °C for 20 min. The sonicated mixture was injected into 7 mL of PBS using a microflow syringe at a rate of 0.5 mL/min (total injection time 14 min), with a magnetic stirrer placed at the bottom of the flask. After stirring overnight, the product was collected by centrifugation at 8000 ×g for 10 min at 4 °C and washed three times with PBS buffer. The solid sample was then freeze-dried, yielding the final T-COP@o-CB NPs with an isolated yield of 43.14% (based on the total mass of T-COP and o-CB). DSPE-PEG2000 (100 mg in chloroform) was mixed with T-COP@o-CB (10 mg, 1:10 w/w), stirred for 24 h, then subjected to rotary evaporation. The crude product was dialyzed (MWCO 100 kDa) against 500 mL deionized water at 4 °C for 48 h (water changed every 6 h). Subsequently, chloroform was removed by rotary evaporation under reduced pressure. Successful PEGylation was confirmed by zeta potential shift from –5.51 mV (uncoated) to –0.174 mV (PEGylated). The sample was freeze-dried to obtain T-COP@o-CB NPs. Characterization The morphology and size of nanoparticles were examined using transmission electron microscopy (TEM). The hydrodynamic diameter was measured with a particle size analyzer. Absorption spectra and fluorescence properties were characterized using ultraviolet and fluorescence spectrophotometers, respectively. Hemolysis of T-COP@o-CB NPs T-COP@o-CB NPs with different concentrations (0, 12.5, 25, 50, 75 and 100 μg mL−1) were prepared in PBS (pH = 7.4). The whole blood of BALB/c mice was obtained by eyeball blood collection and collected in anticoagulant tubes containing sodium citrate. Lower blood cells were obtained by centrifugation at 1790 ×g (4000 rpm, rotor radius 10 cm) for 5 min. Next, 1 mL of T-COP@o-CB NPs solutions with different concentrations, ultrapure water, and PBS were added to 20 μL of blood cells. The mixture was incubated at 37 °C for 4 h and then centrifuged for 15 min. The 100 μL upper solution was transferred to a 96-well plate, and the absorbance value of the sample at 540 nm was measured using a multifunctional microplate reader. Hemolysis rate = (OD (sample group) - OD (PBS group))/(OD (pure water group) - OD (PBS group)) × 100%. In vitro Cytotoxicity and Apoptosis Assay Cell Culture: DMEM medium containing 10% FBS and 1% penicillin-streptomycin was used to culture the murine breast cancer line (4T1 cells) at 37 °C in a humidified incubator with 5% CO2. 4T1 cells were seeded in a 96-well plate at a density of 1×104 cells per well and cultured for 24 hours until reaching approximately 80–90% confluency. The medium was then removed, and the cells were washed with phosphate-buffered saline (PBS). Subsequently, the cells were treated with fresh medium containing varying concentrations of T-COP@o-CB NPs (0, 12.5, 25, 50, 100, and 250 μg·mL−1) for 24, 48, and 72 hours. After treatment, the drug-containing medium was aspirated, and the cells were washed with PBS. Next, 100 μL of a CCK-8/medium mixture was added to each well, followed by incubation at 37°C in the dark for 30 minutes. Cell viability was determined by measuring absorbance at 450 nm using a microplate reader. 4T1 cells were plated in a 6-well plate at a density of 2×105 cells per well and cultured until they reached 80–90% confluency. After washing with PBS, the cells were treated with either PBS or T-COP@o-CB NPs. Following treatment, all media were discarded, and the cells were washed with Buffer. The cells were then stained with Calcein-AM and propidium iodide (PI) staining solution for 30 minutes in the dark. Finally, the cells were washed three times with PBS, and fluorescent images were acquired using a fluorescence microscope for analysis. Cell Uptake The following experiment was conducted to study the uptake of T-COP@o-CB NPs by malignant cells. 4T1 cells were seeded into 6-well plates at a density of 5 × 105 cells per well and allowed to grow overnight at 37 °C in a 5% CO2 oven. Then, various T-COP@o-CB NPs concentrations (0, 12.5, 25, 50, 100, and 250 μg mL−1) were added to the cells and incubated for 24 h. After washing the cells with PBS three times, they were harvested via trypsinization, washed with fresh culture medium, and counted. A total of 1×106 cells were suspended in 500 μL of nitric acid for digestion, and the boron levels were measured in triplicate using ICP-OES. ICP-OES details: digestion – 3 mL HNO3, microwave program (120 °C/30 min pre; 130 °C/3 min, 150 °C/10 min, 180 °C/30 min), final volume 10 mL (dilution factor 1). Calibration 0–10 mg/L (6 points, R2>0.999). No internal standard; QC recovery 95–105%. Agilent 5110 ICP-OES (1250 W, 249.773 nm). The cells were then treated with T-COP@o-CB NPs at a final concentration of 50 μg/mL (normalized based on boron content) and incubated for 0, 6, and 12 h. Live/Dead Cell Staining 4T1 cells were seeded into 6-well plates at a density of 5 × 105 cells per well and cultured overnight. The cells were then treated with T-COP@o-CB NPs at a final concentration of 50 μg/mL (normalized based on boron content) and incubated for 0, 6, and 12 h, the medium was removed and washing the cells with PBS three times. Subsequently, the cells were stained with Calcein-AM and propidium iodide (PI) in the dark at 37 °C for 15 minutes, followed by washing with PBS to remove excess dye, and then observed by a confocal fluorescence microscope under 425 nm excitation. Tumor-Bearing Animal Models All animal procedures were performed in accordance with the Guidelines for Institutional Animal Care and Use Committee, and approved by the Animal Ethics Committee of Shanxi Medical University (No. SYDL2019002). Female Balb/c mice (6–8 weeks old, 18–20 g) were obtained from Beijing Charles River Laboratory Animal Technology Co., Ltd. (China). To establish the tumor model, 4T1 cells (1 × 106 cells, 60 μL) were subcutaneously injected 4T1 cells into the right shoulder of each mice. In vivo Fluorescence Imaging of T-COP@o-CB NPs Fluorescent images of 4T1 tumor-bearing mice were recorded after anesthetized by inhalation of a mixture of 2% isoflurane/oxygen. After situ injection of 50 μL of T-COP@o-CB NPs solution into the mice, whole body fluorescence scanning was performed at specific time points (0, 4, 8, 12, 24, 48, and 72 h) on mice using an IVIS Lumina III in vivo imaging system with an excitation wavelength of 430 nm and emission monitored at 670 nm. (IVIS Imaging Systems with the CCD ranges from 1024×1024 to 2048×2048 pixels in size, the image exposure time is 10s). The mice were sacrificed after 72 h. Tumor, spleen, liver, kidney, heart, and lung were collected after dissection for ex vivo imaging. In vivo BNCT of T-COP@o-CB NPs Mice bearing 4T1 tumors were randomly divided into three groups (n = 5 per group): (1) PBS, (2) T-COP@o-CB NP, and (3) T-COP@o-CB NP + N. When the tumor volume reached approximately 100–150 mm3, each mouse received a single intratumoral injection of 50 μL of a 100 μg/mL solution of the respective reagent. Mice given three separate injections were irradiated with a thermal neutron flux of 1.9×109 cm−2·s−1 for 30 min. The tumor volumes of all mice were estimated daily and were calculated using the equation: volume = (length × width2)/2. The tumor volume was plotted versus time to analyze the therapeutic effects in the different groups. The body weights and physical signs were also monitored simultaneously as indicators of systemic toxicity. When the tumor size reached approximately 1000 mm3 or the loss reaches 20% of the total body weight, the mice will be removed from the experimental group and euthanized. Tumor tissues and major organs (heart, liver, spleen, lung, kidney) were collected for H&E staining and further histological analysis. Statistical Analysis All quantitative results were expressed as the mean± standard deviation (SD) from at least three independent experiments. Statistical analysis was performed using Student’s t-test (two group com-parison) and one-way ANOVA with Tukey’s honest significant difference post hoc test (multiple groups comparison). Differences were considered statistically significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****). Results and Discussion Preparation and Characterization of the T-COP Porphyrins, as naturally occurring optically active macrocycles, possess strong visible-light absorption and red fluorescence.21 These properties render them highly attractive for applications in photocatalysis, photodynamic therapy, photoelectric conversion, and related fields.22 We synthesized a porphyrin functionalized with boronic acid groups (ATPP) as a ligand via a straightforward two-step method in moderate yield. The structure of ATPP was fully characterized by 1H NMR (Figures S1 and S2, Supporting Information). Inspired by prior work, the synthesis of T-COP was achieved by the condensation of ATPP with the 1,4- benzenediboronic acid (BDBA), in which a layered hexagonal framework was expected to form upon dehydration (Figure 2A). The synthesis was carried out by heating BDBA at 120 °C for 72 h in a mesitylene-dioxane mixture within a sealed Pyrex tube. Subsequently, transmission electron microscopy (TEM) analysis reveals that T-COP consists of polydisperse layered nanoparticles (Figure 2B). To verify the successful synthesis of T-COP, Fourier transform infrared spectroscopy (FT-IR) and UV-vis absorption were employed for its characterization. The FT-IR spectra (Figure 2C) displayed characteristic B–O stretching vibrations at 1342 cm−1 and 1378 cm−1. Compared to the initial materials, a new absorption peak appeared at 711 cm−1 due to the formation of the B3-O3 bond, which demonstrating the successful condensation between the ATPP and BDBA. The UV-vis absorption spectrum of T-COP shows a characteristic absorption peak at 425 nm, indicating the presence of porphyrin structures within the framework (Figure 2D). The Brunauer-Emmett-Teller (BET) surface area of T-COP is 219 cm2g−1, with a total pore volume of 0.22 cm3g−1 (pore size, 3.24 nm) (Figure 2E). Collectively, these results verify the successful construction of T-COP through covalently linking BDBA and ATPP building blocks. Figure 2Characterization of T-COP. (A) The synthetic procedure and mode for T-COP. (B) TEM image of T-COP. (C) FT-IR spectra of T-COP, ATPP, and BDBA. (D) UV−vis absorption spectra of T-COP, ATPP, and BDBA. (E) Nitrogen adsorption (black dots)-desorption (red dots) isotherms at 77 K of T-COP.The image A shows the synthesis process of T-COP, combining ATPP and BDBA using 1,3,5-trimethylbenzene and 1,4-dioxane at 120 degrees Celsius for 72 hours, resulting in a complex structure. The image B shows a transmission electron microscopy image of T-COP, revealing polydisperse layered nanoparticles. The image C shows Fourier transform infrared spectra of T-COP, ATPP and BDBA, highlighting B-O stretching vibrations at 1378 and 1342 cm superscript negative 1 and a B subscript 3-O subscript 3 bond at 711 cm superscript negative 1. The image D shows UV-vis absorption spectra of T-COP, ATPP and BDBA, with a peak at 425 nm indicating porphyrin structures. The image E shows nitrogen adsorption-desorption isotherms at 77 K for T-COP, illustrating adsorption and desorption curves with nitrogen uptake in cm superscript 3 g superscript negative 1 against relative pressure P over P subscript 0.Five images showing synthesis, TEM, FT-IR, UV-vis spectra and nitrogen adsorption-desorption of T-COP. Characterization of T-COP. (A) The synthetic procedure and mode for T-COP. (B) TEM image of T-COP. (C) FT-IR spectra of T-COP, ATPP, and BDBA. (D) UV−vis absorption spectra of T-COP, ATPP, and BDBA. (E) Nitrogen adsorption (black dots)-desorption (red dots) isotherms at 77 K of T-COP. Preparation and Characterizations of the T-COP@o-CB NPs Ortho-Carborane (o-CB) is a highly compact cage-like boron cluster molecule with a core skeleton diameter of approximately 5 Å, expanding to about 7–8 Å when including the surface hydrogen atoms. Its defining characteristic is a “small yet robust” structure that accommodates a high density of boron atoms within a minimal volume while exhibiting remarkable chemical inertness. This constitutes a core structural advantage for its role as an efficient boron delivery agent in BNCT.23 On the other hand, the boronate ester-linked T-COP framework incorporates porphyrin units. These units serve as electron-rich moieties with high π-electron density, effectively enhancing the electron-donating capability of the framework. Boron atoms in the o-CB formed a B-O coordination with the boronate ester bond on the surface of T-COP, resulting in a nanoplatform (T-COP@o-CB) coloaded with o-CB small molecule boron drugs. It is noteworthy that o-CB is intrinsically an electron-deficient cluster, while the boronate ester-linked T-COP framework that incorporates porphyrin is an electron-rich system, suggesting a potential for electronic complementarity between the two components. A high loading of o-CB into the porous T-COP framework was achieved via water-bath ultrasonication assisted by stirring. Subsequent encapsulation within DSPE-PEG2000 micelles yielded the final nanocomposite, T-COP@o-CB NPs. Transmission Electron Microscopy (TEM) characterization revealed a clustered morphology for the material (Figure 3A), and Dynamic Light Scattering (DLS) measurements indicated a hydrodynamic diameter primarily in the range of 283 nm with polydispersity index (PDI) = 0.272 (Figure 3B). The zeta potential shifted from –5.51 mV before PEGylation to –0.174 mV after DSPE-PEG2000 modification, a near-neutral value that is typical for PEGylated nanomaterials because the neutral PEG brush shifts the shear plane outward and provides steric stabilization rather than electrostatic repulsion (Figure 3C). To investigate the electronic structure and interactions within the material before and after composite formation, we conducted UV-Vis spectroscopy analysis using acetonitrile as the solvent. As shown in Figure 3D, following the loading of o-CB, a characteristic absorption peak attributable to o-CB emerged at 245 nm. Concurrently, the intensity of the characteristic Soret band absorption peak of the porphyrin unit at 425 nm was notably enhanced. This suggests that the introduction of o-CB may have influenced the electronic environment of the porphyrin units or the intramolecular charge transfer processes. Furthermore, owing to the incorporation of the porphyrin units, the composite material exhibited distinct fluorescent properties in PBS buffer solution (Figure 3E). However, the phenomenon of decreasing fluorescence intensity with increasing concentration (Figure 3F) aligns with the typical characteristics of Aggregation-Caused Quenching (ACQ). Due to the intrinsic fluorescent properties of the porphyrin units, we systematically characterized the fluorescence dynamics of T-COP@o-CB NPs. Time-resolved fluorescence decay measurements were performed under excitation wavelengths of 320 nm and 500 nm, respectively. The lifetime fitting results indicate that the average fluorescence lifetime of T-COP@o-CB NPs is approximately 0.15 μs, as shown in Figure S3. Moreover, the fluorescence intensities measured at different excitation wavelengths showed no significant difference (Figure 3G). Furthermore, the time-resolved fluorescence (TRF) spectra of T-COP@o-CB NPs were further recorded. After turning off the excitation source, a distinct fluorescent signal could still be detected (Figure 3H), further confirming the long-lived luminescent characteristics of the material. This characteristic enables the complete avoidance of background fluorescence interference associated with real-time excitation, demonstrating its substantial application potential as a high-performance, low-background optical material. In addition, quantitative analysis of the boron content via Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) showed a substantial increase in total boron content from 10.01% to 28.82% after loading, strongly corroborating the high loading capacity of T-COP (Figure 3I). These quantitative data further confirm the high loading capacity of T-COP as a drug delivery carrier. Figure 3Characterization of T-COP@o-CB NPs. (A) TEM image of T-COP@o-CB NPs. (B) Hydrodynamic diameters and polydispersity index of T-COP@o-CB NPs. (C) Zeta potential (D) UV−vis spectra and (E) Fluorescence spectra of T-COP@o-CB. (F) Fluorescence emission spectra of T-COP@o-CB NPs with different concentration. (G) Fluorescence lifetime curve of T-COP@o-CB NPs. (H) Steady-state and transient fluorescence spectra of T-COP@o-CB NPs. (I) Comparison of boron content before and after drug loading (n = 3 independent experiments, ****P value <0.0001).Image A: TEM image of T-COP@o-CB NPs, scale 200 nm. Image B: Graph showing hydrodynamic diameter (283 nm) with a polydispersity index of 0.272. Image C: Bar graph of zeta potential, -5.51 mV for T-COP@o-CB and -0.174 mV for T-COP@o-CB NPs. Image D: UV-vis spectra comparing o-CB, T-COP and T-COP@o-CB NPs. Image E: Fluorescence intensity graph comparing o-CB, T-COP and T-COP@o-CB NPs. Image F: Fluorescence intensity for concentrations 50-1000 µg/mL. Image G: Fluorescence lifetime curve for excitation wavelengths 320 nm and 500 nm. Image H: Normalized intensity graph comparing steady-state and transient fluorescence. Image I: Bar graph showing increased boron concentration in T-COP@o-CB compared to T-COP.T-COP@o-CB NPs: TEM, size, zeta, UV-vis, fluorescence, lifetime, boron graphs. Characterization of T-COP@o-CB NPs. (A) TEM image of T-COP@o-CB NPs. (B) Hydrodynamic diameters and polydispersity index of T-COP@o-CB NPs. (C) Zeta potential (D) UV−vis spectra and (E) Fluorescence spectra of T-COP@o-CB. (F) Fluorescence emission spectra of T-COP@o-CB NPs with different concentration. (G) Fluorescence lifetime curve of T-COP@o-CB NPs. (H) Steady-state and transient fluorescence spectra of T-COP@o-CB NPs. (I) Comparison of boron content before and after drug loading (n = 3 independent experiments, ****P value <0.0001). Cellular Evaluation Following the systematic characterization of the T-COP@o-CB NPs nanocomposite, we further evaluated its biological effects at the cellular level. Cytotoxicity against 4T1 cells was assessed via CCK-8 assay (Figure 4A). Even at a high concentration of 250 μg mL−1, T-COP@o-CB NPs exhibited excellent biocompatibility, indicating high in vitro biosafety. Hemocompatibility tests further showed no significant hemolysis within the concentration range of 0–100 μg mL−1 (Figure 4B), providing preliminary evidence for in vivo safety. Efficient delivery of boron agents to cancer cells is crucial for achieving precise BNCT radiotherapy. Therefore, we quantitatively measured the boron uptake capacity of 4T1 cells when treated with varying concentrations of T-COP@o-CB NPs (12.5, 25, 50, 100, and 250 μg mL−1). After 24 hours of co-incubation, the intracellular boron content showed a significant concentration-dependent increase. Integrating cytotoxicity and biosafety data, a concentration of 50 μg mL−1 was selected for subsequent experiments (Figure 4C). Live/dead cell staining corroborated these findings: at this concentration, 4T1 cells co-incubated with the material maintained high viability and intact morphology, consistent with CCK-8 results (Figure 4D). To visualize cellular internalization and subcellular distribution, confocal laser scanning microscopy was employed with DAPI-stained nuclei (Figure 4E). Within 6 h of co-incubation, T-COP@o-CB NPs were efficiently internalized and uniformly distributed in the cytoplasm, indicating rapid uptake and favorable intracellular dispersion. Extended observation revealed prolonged intracellular retention, advantageous for sustained boron accumulation at tumor sites. Flow cytometry analysis and statistical evaluation of fluorescence intensity revealed that T-COP@o-CB nanoparticles were effectively internalized by tumor cells within 6 hours, and their intracellular fluorescence intensity showed no significant difference compared to that at 12 hours (Figure 4F and G). These results indicate that the material exhibits high cellular uptake efficiency and can achieve effective endocytosis within a relatively short time frame. Figure 4Cellular uptake and cytotoxicity of T-COP@o-CB NPs. (A) Cytotoxicity of T-COP@o-CB NPs. (B) Hemolysis experiment. (C) The boron levels in 4T1 cells were measured after incubation with varying concentrations of T-COP@o-CB NPs. Statistical significance was calculated via Two-tailed unpaired t-test, n = 3, mean ± s.d., ****p = 0.0161. (D) Calcein-AM/PI staining images for analysis of live/dead cells in 4T1 cells after different treatments: control, T-COP@o-CB NPs. Scale bar:100 μm. (E) Confocal microscopy images of 4T1cells incubated with T-COP@o-CB NPs for 6 h and 12 h. Scale bar = 20 μm. (F) Cell internalization of samples and 4T1 cells after incubation for 6 and 12 h was detected by flow cytometry. (G) The fluorescence intensity of 4T1 cells treated with T-COP@o-CB NPs at different time points was detected by flow cytometry, n = 3.Image A presents bar graphs of cell viability over 24, 48 and 72 hours at concentrations of 0 to 250 µg/mL. Image B displays hemolysis ratios at concentrations from water to 100 µg/mL, with test tubes showing red coloration. Image C features a bar graph of boron concentration in ppm at 12.5 to 250 µg/mL, highlighting statistical significance. Image D includes Calcein-AM and PI staining images for control and T-COP@o-CB NPs, with a 100 µm scale bar. Image E shows confocal microscopy images of cells at 0, 6 and 12 hours with DAPI and T-COP@o-CB NPs staining, with a 20 µm scale bar. Image F presents flow cytometry graphs of T-COP@o-CB NPs at 6 and 12 hours versus control. Image G illustrates a bar graph of mean fluorescence intensity at 6 and 12 hours.T-COP@o-CB NPs impact cell viability, hemolysis, boron levels and fluorescence intensity. Cellular uptake and cytotoxicity of T-COP@o-CB NPs. (A) Cytotoxicity of T-COP@o-CB NPs. (B) Hemolysis experiment. (C) The boron levels in 4T1 cells were measured after incubation with varying concentrations of T-COP@o-CB NPs. Statistical significance was calculated via Two-tailed unpaired t-test, n = 3, mean ± s.d., ****p = 0.0161. (D) Calcein-AM/PI staining images for analysis of live/dead cells in 4T1 cells after different treatments: control, T-COP@o-CB NPs. Scale bar:100 μm. (E) Confocal microscopy images of 4T1cells incubated with T-COP@o-CB NPs for 6 h and 12 h. Scale bar = 20 μm. (F) Cell internalization of samples and 4T1 cells after incubation for 6 and 12 h was detected by flow cytometry. (G) The fluorescence intensity of 4T1 cells treated with T-COP@o-CB NPs at different time points was detected by flow cytometry, n = 3. In vivo-Distribution of T-COP@o-CB NPs To overcome physiological barriers in solid tumors—such as elevated interstitial fluid pressure and heterogeneous blood perfusion—intratumoral injection was employed to ensure sufficient drug-tumor cell contact. The intratumoral penetration and retention of T-COP@o-CB NPs were evaluated by administering nanoparticles to tumor-bearing mice. Whole-body fluorescence imaging was performed at designated time points (0, 4, 8, 12, 24, 48, and 72 h) using an IVIS Lumina III in vivo imaging system (Figure 5). By analyzing the temporal dynamics of fluorescence signals in the tumor region, we investigated the in vivo distribution profile of the nanomaterial. The results indicated that over the 72-hour period following injection, the drug continued to diffuse within the tumor without significant leakage into the surrounding peritumoral normal tissues. This distribution characteristic helps confine the radiation effects predominantly to the tumor region during subsequent neutron irradiation, thereby minimizing unnecessary damage to adjacent healthy tissues. Consequently, it enhances the local drug concentration within the tumor and further improves the eradication of tumor cells. Figure 5Fluorescence imaging of T-COP@o-CB NPs in 4T1 tumor-bearing mice in vivo and in vitro. (Tumor were indicated by red circle). (A) In vivo fluorescence imaging of 4T1 tumor-bearing mice. (B) Ex vivo fluorescence imaging of tumors and major organs (heart, liver, spleen, lung, kidney) harvested at 72 h after intratumoral injection of T‑COP@o‑CB NPs. (C) Quantitative changes in fluorescence intensity at the tumor site from 0 to 72 h.The image A shows fluorescence imaging of 4T1 tumor-bearing mice at different time points: pre, 0, 4, 8, 12, 24, 48 and 72 hours. The tumor area is highlighted, showing changes in fluorescence intensity over time. The image B shows ex vivo imaging of organs including the lung, heart, kidney, liver, spleen and tumor, with the tumor showing significant fluorescence. The image C shows a bar graph with the x-axis labeled 'Time (h)' and the y-axis labeled 'Mean fluorescence intensity'. The graph displays consistent fluorescence intensity from 0 to 72 hours, indicating stable retention of the nanoparticles in the tumor site.Fluorescence imaging of 4T1 tumor-bearing mice over 72 hours, organ imaging and intensity graph. Fluorescence imaging of T-COP@o-CB NPs in 4T1 tumor-bearing mice in vivo and in vitro. (Tumor were indicated by red circle). (A) In vivo fluorescence imaging of 4T1 tumor-bearing mice. (B) Ex vivo fluorescence imaging of tumors and major organs (heart, liver, spleen, lung, kidney) harvested at 72 h after intratumoral injection of T‑COP@o‑CB NPs. (C) Quantitative changes in fluorescence intensity at the tumor site from 0 to 72 h. In vivo BNCT Efficacy of T-COP@o-CB NPs To systematically evaluate the synergistic antitumor efficacy and biosafety of T-COP@o-CB NPs in vivo, a subcutaneous 4T1 breast tumor model was established in BALB/c mice. During neutron irradiation, mice were anesthetized and positioned with heads oriented toward the neutron beam. The thermal neutron beam was collimated to expose only the upper body (including tumor, head, forelimbs, and thorax), while a shielding apparatus protected major abdominal organs, achieving highly localized irradiation. The tumor-bearing mice were randomly divided into three groups: a PBS control group, a T-COP@o-CB NPs monotherapy group (5.6 mg·kg−1), and a T-COP@o-CB NPs plus neutron irradiation group (T-COP@o-CB NPs+N, where N denotes neutron irradiation). Twelve hours after the injection of T-COP@o-CB NPs, the corresponding groups of mice received localized thermal neutron irradiation at a flux of 1.9 × 109 n·cm−2·s−1 for 30 minutes. Tumor volume and body weight were monitored regularly post-treatment, and the animals were euthanized for tissue collection on day 18 (Figure 6A). Figure 6Comparing with other groups, mice injected with T-COP@o-CB NPs followed by neutron irradiation showed significantly more effective tumor suppression without exhibiting systemic toxicity. (A) One-time injection schematic representation of the timeline of the experimental period. (B and C) Average tumor volumes of each group of mice (n = 5 independent experiments, *P value < 0.0190). (D) Body weight curve of the individual mouse at indicated time points after BNCT experiments (n = 5 independent experiments, **P value < 0.0016). (E) Survival curve of the individual mouse at indicated time points after BNCT experiments. (F) Schematic representation of tumor volumes in mice from different treatment groups post-treatment (n = 5). (G) H&E-stained of heart, liver, spleen, and lung slices collected from different groups of mice 3 weeks day after various treatments, Scale bar = 100 μm. (H) ALT, (I) AST, and (J) creatinine levels in serum were quantified. Data are shown as Mean ± S.D. from three independent experiments (n=3).Image A outlines the experimental timeline: xenografts on day -7, drug injection on day -1, neutron irradiation on day 0 and sacrifice on day 18. Image B presents three tumor volume graphs post-BNCT: 'Control' and 'T-COP@o-CB NPs' show similar growth to 1000 mm³ over 20 days, while 'T-COP@o-CB NPs plus N' shows slower growth. Image C compares tumor volumes, highlighting significant differences with an asterisk. Image D depicts body weight changes post-BNCT, marked as not significant. Image E illustrates survival curves for the three groups. Image F displays tumor photographs from each group. Image G shows H&E-stained tissue slices of heart, liver, spleen, lung and kidney from control and T-COP@o-CB NPs groups, with a 100 µm scale bar. Image H presents a bar graph of ALT levels, marked as not significant. Image I shows AST levels, also not significant. Image J displays creatinine levels, with a significant difference indicated by an asterisk.T-COP@o-CB NPs study: neutron irradiation effects on mouse tumors, with graphs and tissue analysis. Comparing with other groups, mice injected with T-COP@o-CB NPs followed by neutron irradiation showed significantly more effective tumor suppression without exhibiting systemic toxicity. (A) One-time injection schematic representation of the timeline of the experimental period. (B and C) Average tumor volumes of each group of mice (n = 5 independent experiments, *P value < 0.0190). (D) Body weight curve of the individual mouse at indicated time points after BNCT experiments (n = 5 independent experiments, **P value < 0.0016). (E) Survival curve of the individual mouse at indicated time points after BNCT experiments. (F) Schematic representation of tumor volumes in mice from different treatment groups post-treatment (n = 5). (G) H&E-stained of heart, liver, spleen, and lung slices collected from different groups of mice 3 weeks day after various treatments, Scale bar = 100 μm. (H) ALT, (I) AST, and (J) creatinine levels in serum were quantified. Data are shown as Mean ± S.D. from three independent experiments (n=3). Notably, the T-COP@o-CB NPs+N combination therapy group exhibited the most significant tumor growth inhibition. The final average tumor volume in this group was only 5.67-fold the initial volume (Figure 6B and C), which was substantially lower than that of the PBS control group (20.77-fold) and the T-COP@o-CB NPs monotherapy group (14.76-fold). This result clearly demonstrates the superior antitumor efficacy of the combination strategy. This effect is primarily attributed to the thermally induced 10B(n,α)7Li neutron capture reaction, which is triggered by the localized enrichment of the boron carrier and leads to precise cellular-scale damage and irreversible injury within the boron-labeled tumor cells. Throughout the experimental period, no significant differences in body weight were observed among the treatment groups (Figure 6D), indicating the long-term biocompatibility of T-COP@o-CB NPs in vivo. Furthermore, neutron irradiation significantly extended the survival of tumor-bearing mice, with all irradiated animals surviving until the experimental endpoint (day 18). A comparison of tumors across different treatment groups further confirmed that boron neutron capture therapy based on T-COP@o-CB NPs achieved satisfactory tumor control efficacy (Figure 6E and F). This further confirms the satisfactory tumor control efficacy of the T-COP@o-CB NPs-based boron neutron capture therapy. Histopathological analysis of major organs (heart, liver, spleen, lung, and kidney) by hematoxylin and eosin (H&E) staining revealed no obvious signs of inflammation or tissue damage (Figure 6G). Compared with the control group that did not receive neutron therapy, mice injected with T-COP@o-CB NPs showed no significant increase in serum levels of ALT, AST, or creatinine (Figures 6H–J), with all hepatic and renal function indicators remaining within normal physiological ranges. Furthermore, complete blood count results supported the conclusion of systemic safety (Supplementary Figure S4 and Table S1). Collectively, these histopathological and serological data demonstrate that T-COP@o-CB NPs combined with neutron irradiation significantly inhibited tumor growth without inducing noticeable systemic toxicity, thereby providing solid experimental evidence for the favorable biosafety profile of this nanomaterial in vivo. Conclusion We have successfully developed a multifunctional porphyrin-COP-based nanocomposite, T-COP@o-CB NPs, as an effective theranostic agent for BNCT. The material integrates several key features: (1) a crystalline, porous COP structure providing a robust host framework with inherent fluorescence for imaging; (2) a high payload of the boron agent, o-carborane, facilitated by potential host-guest interactions; and (3) PEGylation ensuring colloidal stability and biocompatibility. Systematic evaluation confirms that this platform enables efficient boron delivery to tumor cells, provides a means for optical monitoring of distribution, and, upon neutron irradiation, elicits potent tumor growth inhibition in a murine breast cancer model. The treatment showed a highly favorable safety profile, with no observable damage to major organs. This study not only provides a promising candidate for improving the efficacy and precision of BNCT but also opens avenues for the design of polymer-based theranostic systems for other binary radiotherapy modalities. Future work will focus on elucidating the precise loading mechanism, exploring active targeting strategies, and investigating the long-term biodistribution and therapeutic efficacy in more clinically relevant models.